An exploration of individual- and population-level impact of the 2-dose HPV vaccination schedule in pre-adolescent girls

Human Vaccines and Immunotherapeutics

Volumn 12, Issue 6, 2016, Pages 1381-1393

  Donken, Robine ^a,b   Bogaards, Johannes A ^a   van der Klis, Fiona R M ^a   Meijer, Chris J L M ^b   de Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

antibodies; cervical Intraepithelial neoplasia (CIN); cost effectiveness; genital warts; Human Papillomavirus (HPV) infection; human papillomavirus 16; human papillomavirus 18; immunisation schedule; non inferiority; transmission; vaccination

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ADULT; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CHILD; CLINICAL EFFECTIVENESS; CONDYLOMA ACUMINATUM; COST EFFECTIVENESS ANALYSIS; DOSAGE SCHEDULE COMPARISON; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 11; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 6; IMMUNOGENICITY; MEMORY CELL; OUTCOME ASSESSMENT; PAPILLOMAVIRUS INFECTION; PREVALENCE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCHOOL CHILD; UTERINE CERVIX CARCINOMA IN SITU; VACCINATION; YOUNG ADULT; COST BENEFIT ANALYSIS; IMMUNIZATION; IMMUNOLOGY; PAPILLOMAVIRUS INFECTIONS;

ADOLESCENT; CHILD; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES;

EID: 84976285811     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.1080/21645515.2016.1160978     Document Type: Review

References (58)

1. Food and Drug Administration. Gardasil. 2015; Available from: http://www.fda.gov/BiologicsBloodVaccines/Vaccines/ApprovedProducts/UCM094042
2. European Medicines Agency, Cervarix. 2015. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000721/human_med_000694.jsp&mid=WC0b01ac05-8001d124
3. European Medicines Agency; Gardasil. Available from: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000703/human_med_000805.jsp
4. Center for Disease Control. FDA Licensure of Bivalent Human Papillomavirus Vaccine (HPV2, Cervarix) for Use in Females and Updated HPV Vaccination Recommendations from the Advisory Committee on Immunization Practices (ACIP). 2010; Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a4.htm
5. Center for Disease Control. FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance from the Advisory Committee on Immunization Practices (ACIP). 2015; Available from: http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5920a5.htm.
6. European Medicines Agency, Committee for medicinal products for human use post authorization summary of positive opinion* for Gardasil 2008.
7. European Medicines Agency, Summary of opinion1 (post authorisation) Cervarix. 2011.
8. European Medicines Agency, Assessment report Cervarix. 2013.
9. European Medicines Agency, Assessment report Gardasil 2014.
10. T.F.Leung, A.P.Liu, F.S.Lim, F.Thollot, H.M.Oh, B.W.Lee, L.Rombo, N.C.Tan, R.Rouzier, D.Friel, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine administered according to 2- and 3-dose schedules in girls aged 9–14 years: Results to month 12 from a randomized trial. Hum Vaccin Immunother 2015; 11(7):1689–702; PMID:26062002; http://dx.doi.org/10.1080/21645515.2015.1050570
11. Food and Drug Adminstration. FDA approves Gardasil 9 for prevention of certain cancers caused by five additional types of HPV. 2014; Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm426485.htm
12. WHO SAGE. Evidence based recommendations on Human Papillomavirus (HPV) vaccine schedules. 2014.
13. R.Donken, H.E.De Melker, N.Y.Rots, G.Berbers, M.J.Knol. Comparing vaccines: a systematic review of the use of the non-inferiority margin in vaccine trials. Vaccine 2015; 33(12):1426–32; PMID:25659273; http://dx.doi.org/10.1016/j.vaccine.2015.01.072
14. R.Donken, M.J.Knol, J.A.Bogaards, F.R.Van Der Klis, C.J.Meijer, H.E.De Melker. Inconclusive evidence for non-inferior immunogenicity of two- compared with three-dose HPV immunization schedules in preadolescent girls: A systematic review and meta-analysis. J Infect 2015; 71:61–73; PMID:25709084.
15. European Center for Disease Control. Vaccine Schedule. 2015 Available from: http://vaccine-schedule.ecdc.europa.eu/Pages/Scheduler.aspx
16. Institute Catala d'Oncologica. Summary report. 2015; Available from: www.hpvcentre.com
17. WHO. Immunization schedule by antigen. 2015; Available from: http://apps.who.int/immunization_monitoring/globalsummary/schedules
18. T.B.Turner, W.K.Huh, HPV Vaccines: translating immunogenicity into efficacy. Hum Vaccin Immunother 2015:1–3.
19. S.R.Dobson, S.Mcneil, M.Dionne, M.Dawar, G.Ogilvie, M.Krajden, C.Sauvageau, D.W.Scheifele, T.R.Kollmann, S.A.Halperin, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA 2013; 309(17):1793–802; PMID:23632723.
20. M.Krajden, D.Cook, A.Yu, R.Chow, Q.Su, W.Mei, S.Mcneil, D.Money, M.Dionne, J.Palefsky, et al. Assessment of HPV 16 and HPV 18 antibody responses by pseudovirus neutralization, Merck cLIA and Merck total IgG LIA immunoassays in a reduced dosage quadrivalent HPV vaccine trial. Vaccine 2014; 32(5):624–30; PMID:24055350; http://dx.doi.org/10.1016/j.vaccine.2013.09.007
21. E.Lazcano-Ponce, M.Stanley, N.Munoz, L.Torres, A.Cruz-Valdez, J.Salmeron, R.Rojas, R.Herrero, M.Hernandez-Avila. Overcoming barriers to HPV vaccination: non-inferiority of antibody response to human papillomavirus 16/18 vaccine in adolescents vaccinated with a two-dose vs. a three-dose schedule at 21 months. Vaccine 2014; 32(6):725–32; PMID:24355090; http://dx.doi.org/10.1016/j.vaccine.2013.11.059
22. B.Romanowski, T.F.Schwarz, L.Ferguson, K.Peters, M.Dionne, U.Behre, K.Schulze, P.Hillemanns, P.Suryakiran, F.Thomas, et al. Sustained Immunogenicity of the HPV-16/18 AS04-Adjuvanted Vaccine Administered as a Two-Dose Schedule in Adolescent Girls: Five-Year Clinical Data and Modelling Predictions from a randomized study. Hum Vaccin Immunother. 2016 Jan 2; 12(1):20-9’’, For 47 via Science Direct’’Papillomavirus Research Volume 1, December 2015, Pages 59–73.
23. B.Romanowski, T.F.Schwarz, L.M.Ferguson, M.Ferguson, K.Peters, M.Dionne, K.Schulze, B.Ramjattan, P.Hillemanns, U.Behre, et al. Immune response to the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose or 3-dose schedule up to 4 years after vaccination: results from a randomized study. Hum Vaccin Immunother 2014; 10(5):1155–65; PMID:24576907; http://dx.doi.org/10.4161/hv.28022
24. B.Romanowski, T.F.Schwarz, L.M.Ferguson, K.Peters, M.Dionne, K.Schulze, B.Ramjattan, P.Hillemanns, G.Catteau, K.Dobbelaere, et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared with the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011; 7(12):1374–86; PMID:22048171; http://dx.doi.org/10.4161/hv.7.12.18322
25. M.Safaeian, C.Porras, Y.Pan, A.Kreimer, J.T.Schiller, P.Gonzalez, D.R.Lowy, S.Wacholder, M.Schiffman, A.C.Rodriguez, et al. Durable antibody responses following one dose of the bivalent human papillomavirus L1 virus-like particle vaccine in the Costa Rica Vaccine Trial. Cancer Prev Res (Phila) 2013; 6(11):1242–50; PMID:24189371; http://dx.doi.org/10.1158/1940-6207.CAPR-13-0203
26. M.Hernandez-Avila, L.Torres, M.Stanley, J.Salmeron, A.Cruz-Valdez, N.Munoz, R.Herrero, I.F.Villasenor-Ruiz, E.Lazcano-Ponce. Evaluation of the immunogenicity of the quadrivalent HPV vaccine using two versus three doses at month 21: An epidemiological surveillance mechanism for alternate vaccination schemes. Hum Vaccin Immunother, 2016; 12(1):30-8; http://dx.doi.org/10.1080/21645515.2015.1058458
27. E.A.Joura, S.K.Kjaer, C.M.Wheeler, K.Sigurdsson, O.E.Iversen, M.Hernandez-Avila, G.Perez, D.R.Brown, L.A.Koutsky, E.H.Tay, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine 2008; 26(52):6844–51; PMID:18930097; http://dx.doi.org/10.1016/j.vaccine.2008.09.073
28. M.Mollers, J.M.Vossen, M.Scherpenisse, F.R.Van Der Klis, C.J.Meijer, H.E.De Melker. Review: current knowledge on the role of HPV antibodies after natural infection and vaccination: implications for monitoring an HPV vaccination programme. J Med Virol 2013; 85(8):1379–85; PMID:23722396; http://dx.doi.org/10.1002/jmv.23616
29. T.Waterboer, P.Sehr, K.M.Michael, S.Franceschi, J.D.Nieland, T.O.Joos, M.F.Templin, M.Pawlita. Multiplex human papillomavirus serology based on in situ-purified glutathione s-transferase fusion proteins. Clin Chem 2005; 51(10):1845–53; PMID:16099939; http://dx.doi.org/10.1373/clinchem.2005.052381
30. S.L.Block, T.Nolan, C.Sattler, E.Barr, K.E.Giacoletti, C.D.Marchant, X.Castellsague, S.A.Rusche, S.Lukac, J.T.Bryan, et al. Comparison of the immunogenicity and reactogenicity of a prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in male and female adolescents and young adult women. Pediatrics 2006; 118(5):2135–45; PMID:17079588; http://dx.doi.org/10.1542/peds.2006-0461
31. C.Pedersen, T.Petaja, G.Strauss, H.C.Rumke, A.Poder, J.H.Richardus, B.Spiessens, D.Descamps, K.Hardt, M.Lehtinen, et al. Immunization of early adolescent females with human papillomavirus type 16 and 18 L1 virus-like particle vaccine containing AS04 adjuvant. J Adolesc Health 2007; 40(6):564–71; PMID:17531764; http://dx.doi.org/10.1016/j.jadohealth.2007.02.015
32. M.Safaeian, A.Ghosh, C.Porras, S.W.Lin, A.C.Rodriguez, M.Schiffman, S.Wacholder, T.Kemp, P.Gonzalez, N.Wentzensen, et al. Direct comparison of HPV16 serological assays used to define HPV-naive women in HPV vaccine trials. Cancer Epidemiol Biomarkers Prev 2012; 21(9):1547–54; PMID:22752082; http://dx.doi.org/10.1158/1055-9965.EPI-12-0558
33. R.Sankaranarayanan, P.R.Prabhu, M.Pawlita, T.Gheit, N.Bhatla, R.Muwonge, B.M.Nene, P.O.Esmy, S.Joshi, U.R.Poli, et al. Immunogenicity and HPV infection after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre prospective cohort study. Lancet Oncol 2015.
34. M.A.Stanley, S.L.Sudenga, A.R.Giuliano, Alternative dosage schedules with HPV virus-like particle vaccines. Expert Rev Vaccines 2014; 13(8):1027–38; PMID:25001893; http://dx.doi.org/10.1586/14760584.2014.935767
35. M.Boxus, L.Lockman, M.Fochesato, C.Lorin, F.Thomas, S.L.Giannini. Antibody avidity measurements in recipients of Cervarix vaccine following a two-dose schedule or a three-dose schedule. Vaccine 2014; 32(26):3232–6; PMID:24731816; http://dx.doi.org/10.1016/j.vaccine.2014.04.005
36. K.K.Smolen, L.Gelinas, L.Franzen, S.Dobson, M.Dawar, G.Ogilvie, M.Krajden, E.S.Fortuno, 3rd, T.R.Kollmann. Age of recipient and number of doses differentially impact human B and T cell immune memory responses to HPV vaccination. Vaccine 2012; 30(24):3572–9; PMID:22469863; http://dx.doi.org/10.1016/j.vaccine.2012.03.051
37. M.Stanley. HPV vaccines. Best Pract Res Clin Obstet Gynaecol 2006; 20(2):279–93; PMID:16356772; http://dx.doi.org/10.1016/j.bpobgyn.2005.10.011
38. M.H.Einstein, M.Baron, M.J.Levin, A.Chatterjee, B.Fox, S.Scholar, J.Rosen, N.Chakhtoura, D.Meric, F.J.Dessy, et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III randomized study of healthy women aged 18–45 years. Hum Vaccin 2011; 7(12):1343–58; PMID:22048173; http://dx.doi.org/10.4161/hv.7.12.18281
39. B.Donovan, N.Franklin, R.Guy, A.E.Grulich, D.G.Regan, H.Ali, H.Wand, C.K.Fairley. Quadrivalent human papillomavirus vaccination and trends in genital warts in Australia: analysis of national sentinel surveillance data. Lancet Infect Dis 2011; 11(1):39–44; PMID:21067976; http://dx.doi.org/10.1016/S1473-3099(10)70225-5
40. M.A.Smith, B.Liu, P.Mcintyre, R.Menzies, A.Dey, K.Canfell. Fall in genital warts diagnoses in the general and indigenous Australian population following implementation of a national human papillomavirus vaccination program: analysis of routinely collected national hospital data. J Infect Dis 2015; 211(1):91–9; PMID:25117753; http://dx.doi.org/10.1093/infdis/jiu370
41. J.A.Bogaards, J.Berkhof. Assessment of herd immunity from human papillomavirus vaccination. Lancet Infect Dis 2011; 11(12):896; author reply 896–7; PMID:22115067; http://dx.doi.org/10.1016/S1473-3099(11)70324-3
42. M.Blomberg, C.Dehlendorff, C.Sand, S.K.Kjaer. Dose-Related Differences in Effectiveness of Human Papillomavirus Vaccination Against Genital Warts: A Nationwide Study of 550 000 Young Girls. Clin Infect Dis 2015; 61(5):676–82; PMID:25944340; http://dx.doi.org/10.1093/cid/civ364
43. E.Herweijer, A.Leval, A.Ploner, S.Eloranta, J.F.Simard, J.Dillner, E.Netterlid, P.Sparen, L.Arnheim-Dahlstrom Association of varying number of doses of quadrivalent human papillomavirus vaccine with incidence of condyloma. JAMA 2014; 311(6):597–603; PMID:24519299; http://dx.doi.org/10.1001/jama.2014.95
44. A.R.Kreimer, A.C.Rodriguez, A.Hildesheim, R.Herrero, C.Porras, M.Schiffman, P.Gonzalez, D.Solomon, S.Jimenez, J.T.Schiller, et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011; 103(19):1444–51; PMID:21908768; http://dx.doi.org/10.1093/jnci/djr319
45. A.R.Kreimer, F.Struyf, M.R.Del Rosario-Raymundo, A.Hildesheim, S.R.Skinner, S.Wacholder, S.M.Garland, R.Herrero, M.P.David, C.M.Wheeler, et al. Efficacy of fewer than three doses of an HPV-16/18 AS04-adjuvanted vaccine: combined analysis of data from the Costa Rica Vaccine and PATRICIA trials. Lancet Oncol 2015; 16(7):775–86; PMID:26071347; http://dx.doi.org/10.1016/S1470-2045(15)00047-9
46. K.Kavanagh, K.G.Pollock, A.Potts, J.Love, K.Cuschieri, H.Cubie, C.Robertson, M.Donaghy. Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types. Br J Cancer 2014; 110(11):2804–11; http://dx.doi.org/10.1038/bjc.2014.198
47. J.M.Brotherton, M.Malloy, A.C.Budd, A.M.Saville, K.Drennan, D.M.Gertig. Effectiveness of less than three doses of quadrivalent human papillomavirus vaccine against cervical intraepithelial neoplasia when administered using a standard dose spacing schedule: Observational cohort of young women in Australia. Papillomavirus Research, 2015.
48. E.Crowe, N.Pandeya, J.M.Brotherton, A.J.Dobson, S.Kisely, S.B.Lambert, D.C.Whiteman. Effectiveness of quadrivalent human papillomavirus vaccine for the prevention of cervical abnormalities: case-control study nested within a population based screening programme in Australia. BMJ 2014; 348:g1458; http://dx.doi.org/10.1136/bmj.g1458
49. D.M.Gertig, J.M.Brotherton, A.C.Budd, K.Drennan, G.Chappell, A.M.Saville, Impact of a population-based HPV vaccination program on cervical abnormalities: a data linkage study. BMC Med 2013; 11:227; PMID:24148310; http://dx.doi.org/10.1186/1741-7015-11-227
50. K.G.Pollock, K.Kavanagh, A.Potts, J.Love, K.Cuschieri, H.Cubie, C.Robertson, M.Cruickshank, T.J.Palmer, S.Nicoll, et al. Reduction of low- and high-grade cervical abnormalities associated with high uptake of the HPV bivalent vaccine in Scotland. Br J Cancer 2014; 111(9):1824–30; PMID:25180766; http://dx.doi.org/10.1038/bjc.2014.479
51. N.Van De Velde, M.Brisson, M.C.Boily. Understanding differences in predictions of HPV vaccine effectiveness: A comparative model-based analysis. Vaccine 2010; 28(33):5473–84; PMID:20573580; http://dx.doi.org/10.1016/j.vaccine.2010.05.056
52. J.A.Bogaards, V.M.Coupe, M.Xiridou, C.J.Meijer, J.Wallinga, J.Berkhof. Long-term impact of human papillomavirus vaccination on infection rates, cervical abnormalities, and cancer incidence. Epidemiology 2011; 22(4):505–15; PMID:21540743; http://dx.doi.org/10.1097/EDE.0b013e31821d107b
53. M.Brisson, N.Van De Velde, M.C.Boily, Different population-level vaccination effectiveness for HPV types 16, 18, 6 and 11. Sex Transm Infect 2011; 87(1):41–3; PMID:20924049; http://dx.doi.org/10.1136/sti.2010.044412
54. J.Paavonen, P.Naud, J.Salmeron, C.M.Wheeler, S.N.Chow, D.Apter, H.Kitchener, X.Castellsague, J.C.Teixeira, S.R.Skinner, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374(9686):301–14; PMID:19586656; http://dx.doi.org/10.1016/S0140-6736(09)61248-4
55. E.H.Elbasha, E.J.Dasbach. Impact of vaccinating boys and men against HPV in the United States. Vaccine 2010; 28(42):6858–67; PMID:20713101; http://dx.doi.org/10.1016/j.vaccine.2010.08.030
56. M.Jit, Y.H.Choi, J.F.Laprise, M.C.Boily, M.Drolet, M.Brisson. Two-dose strategies for human papillomavirus vaccination: how well do they need to protect? Vaccine 2014; 32(26):3237–42; PMID:24726246; http://dx.doi.org/10.1016/j.vaccine.2014.03.098
57. M.Jit, M.Brisson, J.F.Laprise, Y.H.Choi. Comparison of two dose and three dose human papillomavirus vaccine schedules: cost effectiveness analysis based on transmission model. BMJ 2015; 350:g7584; PMID:25567037; http://dx.doi.org/10.1136/bmj.g7584
58. J.F.Laprise, M.Drolet, M.C.Boily, M.Jit, C.Sauvageau, E.L.Franco, P.Lemieux-Mellouki, T.Malagon, M.Brisson Comparing the cost-effectiveness of two- and three-dose schedules of human papillomavirus vaccination: a transmission-dynamic modelling study. Vaccine 2014; 32(44):5845–53; PMID:25131743; http://dx.doi.org/10.1016/j.vaccine.2014.07.099